Los Angeles-Area A2 Biotherapeutics (www.a2bio.com) announced the closing of its $71.5M Series B financing round to fund the advancement of its Tmod (engineered T-cell module) platform that reportedly combines activating and blocking mechanisms to kill tumor cells and protect normal cells.
and related near-term product candidates.  Series B investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment. Here are links to related news stories.

https://www.businesswire.com/news/home/20201006005044/en/A2-Biotherapeutics-Closes-71.5M-Series-B-to-Begin-Clinical-Development-of-Its-Potentially-Transformative-Selective-Tumor-Cell-Therapeutics

https://www.prnewswire.com/news-releases/a2-biotherapeutics-closes-71-5m-series-b-to-begin-clinical-development-of-its-potentially-transformative-selective-tumor-cell-therapeutics-301145221.html

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Dan Shores Dan Shores

Dan Shores is a partner at  Rothwell, Figg and founder of its Boston office. He serves companies operating in dynamic biotech and other markets building patent portfolios, litigating complex patent disputes, negotiating strategic collaborations, and conducting due diligence and landscape investigations. Dan has…

Dan Shores is a partner at  Rothwell, Figg and founder of its Boston office. He serves companies operating in dynamic biotech and other markets building patent portfolios, litigating complex patent disputes, negotiating strategic collaborations, and conducting due diligence and landscape investigations. Dan has served companies utilizing the following technologies (without limitation): mRNA; lipid nanoparticles; CAR-T; oligonucleotides; genetically engineered swine organs for xenotransplantation; artificial intelligence for drug discovery; small molecules; biologics, materials science, and numerous other technologies throughout his 20-year career. Dan has a B.S. in engineering with a specialization in materials science from the University of New Hampshire and a J.D. from the Georgetown University Law Center. He is a registered patent attorney licensed to practice before the United States Patent and Trademark Office, and is admitted to practice law in Massachusetts and in the District of Columbia. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts.